February Table of Contents

External Link - article-85018.pdf

Articles in this issue

over 22 years ago

Article

Upping the Ante

over 22 years ago

Article

Knowing When to Pull the Plug On Your Experimental Drug

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

Pharmaceutical Executive Daily: TrumpRx Expands to Offer Over 600 Generic Drugs

ByNicholas Jacobus

May 19th 2026

Inside the Expert Network Guiding TGN-S15 to Market

BySandra Coufal, MD,Nicholas Jacobus

May 19th 2026

TrumpRx Expands to Offer Generic Medications

ByNicholas Jacobus

May 19th 2026

Rethinking Pharma's Go-to-Market Formula

ByMichael Christel,Mike Petroutsas

May 19th 2026

Pharma Funding Roundup: Violet Therapeutics' $4.75 Million Seed Extension Financing, Full-Life Technologies Completes $150 Million Financing

ByNicholas Jacobus

May 19th 2026

February Table of Contents

Articles in this issue

Related Content

Pharmaceutical Executive Daily: TrumpRx Expands to Offer Over 600 Generic Drugs

Inside the Expert Network Guiding TGN-S15 to Market

TrumpRx Expands to Offer Generic Medications

Rethinking Pharma's Go-to-Market Formula

Pharma Funding Roundup: Violet Therapeutics' $4.75 Million Seed Extension Financing, Full-Life Technologies Completes $150 Million Financing

Trending on PharmExec

FDA Makes Leadership Overhaul Following Commissioner Makary’s Departure: Report

The Risks and Benefits of FDA Reviewing Real-Time Data

Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates

FDA Approves Baxdrostat for Uncontrolled Hypertension in First-in-Class Entry

What Pharma Investors Should Expect in the Current Regulatory Environment